CLENE NANOMEDICINE
Clene Nanomedicine is a clinical-stage biopharmaceutical company that focuses on the development of unique therapeutics for neurodegenerative diseases. The company innovated a novel nanotechnology drug platform for the development of a new class of orally-administered neurotherapeutic drugs.
CLENE NANOMEDICINE
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2013-01-01
Address:
Salt Lake City, Utah, United States
Country:
United States
Website Url:
http://www.clene.com
Total Employee:
11+
Status:
Active
Contact:
801-676-9695
Email Addresses:
[email protected]
Total Funding:
121.9 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Accera
Accera is a biotechnology company that engages in the discovery and development of therapeutic drugs for neurodegenerative diseases.
Aclipse Therapeutics
Aclipse Therapeutics focuses on developing differentiated drugs to address diseases with unmet medical needs.
Actuate Therapeutics
Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases.
Adagio Medical
Adagio Medical is engaged in the research and development of treatments for cardiovascular diseases.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Anjarium Biosciences
Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Aprea
Aprea is a biopharmaceutical company that develops novel cancer therapeutics.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Fimecs
FIMECS is a focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases.
HebeCell
HebeCell develops and commercializes cell-based therapeutics to treat incurable diseases.
Impact Biomedicines
Impact Biomedicines is pioneering the development of life-changing treatments for patients.
KalGene Pharmaceuticals
KalGene Pharmaceuticals is a biotech company that develops precision medicine therapeutics for patients suffering from Alzheimer's disease.
LSK BioPharma
LSK BioPharma specializes in clinical development of promising therapies for unmet medical needs in cancer.
Mojave Pharma
Mojave Pharma focuses on the research of novel therapies for neurodegenerative & psychiatric diseases.
Neurimmune Holding
Neurimmune develops innovative immunotherapeutics for human diseases.
Neurotrope Bioscience
Neurotrope Bioscience engages in the development of diagnostic and therapeutic technologies for the treatment of neurodegenerative diseases.
Open Innovation Partners
Open Innovation Partners focuses on the development of cancer therapeutic agents.
PharmatrophiX
PharmatrophiX is a biotech company focused on developing therapeutic drugs to prevent neurodegenerative diseases.
Qlaris Bio
Qlaris Bio focuses on developing novel and innovative therapies for serious and debilitating ophthalmic diseases.
QureBio
QureBio focuses on the research and development of innovative macromolecular biopharmaceuticals.
Sorrento Therapeutics
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
Spinogenix
Spinogenix is a developer of a new class of therapeutics for neurodegenerative and psychiatric diseases.
Synaps Dx
Synaps Dx focuses on the research, development and commercialization for neurodegenerative disorders including Alzheimer’s Disease.
Synapse Medicine
Synapse Medicine provides medication decision solutions to deliver enhanced patient-centered insights for care teams.
Tabomedex Biosciences, Inc.
Tabomedex focuses on the R&D of new drugs related to type 2 diabetes.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
AlloVir
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.
Westlake Therapeutics
The company is committed to the development of a variety of innovative cell therapy products for rare diseases, cancer, etc.
Current Employees Featured
Founder
Stock Details
Investors List
Maryland Department of Housing and Community Development
Maryland Department of Housing and Community Development investment in Grant - Clene Nanomedicine
SymBiosis LLC
SymBiosis LLC investment in Post-IPO Equity - Clene Nanomedicine
SymBiosis LLC
SymBiosis LLC investment in Series D - Clene Nanomedicine
National Multiple Sclerosis Society (NMSS)
National Multiple Sclerosis Society (NMSS) investment in Grant - Clene Nanomedicine
FightMND
FightMND investment in Grant - Clene Nanomedicine
Official Site Inspections
http://www.clene.com Semrush global rank: 3.38 M Semrush visits lastest month: 4.65 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Clene Nanomedicine"
About Us | Clene Inc.
He joins Clene alongside his current role as professor of neurology and Vice Chair of Clinical and Translational Research in the Department of Neurology at UT Southwestern Medical Center in Dallas, TX. ... WHRT), a medical device …See details»
Clene Inc. | Nanomedicine in Pharmaceutical Research
Our Pipeline. Our nanotherapeutic platform enables the creation of clean-surfaced, catalytically-active nanocrystals for therapeutic use. We are advancing a pipeline of these nanotherapeutics to address high unmet medical needs, …See details»
Board of Directors | Clene Inc.
Reed Wilcox co-founded Clene Nanomedicine and has been on our board of directors since 2013. From September 2014 through June 2023, Mr. Wilcox was President, Trustee and member of …See details»
Clene Nanomedicine - Crunchbase Company Profile
Clene Nanomedicine is a clinical-stage biopharmaceutical company that focuses on the development of unique therapeutics for neurodegenerative diseases. The company innovated a novel nanotechnology drug platform for the …See details»
Clene Nanomedicine, Inc. | LinkedIn
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on ...See details»
Clene Inc. - Investor FAQs
Clene Inc. does not pay a dividend and has no current plans for a dividend reinvestment program. 1-801-676-9695 [email protected] @CleneNano. Headquarters and …See details»
Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company
Aug 28, 2024 Clene is pioneering a very unique approach to the treatment of neurodegenerative diseases such as ALS and MS with the use of an oral nanotherapeutic that can be easily …See details»
COMMITTED TO REVOLUTIONIZING THE TREATMENT FOR …
CLENE INC. (Exact name of registrant as specified in its charter) Delaware 85-2828339 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 6550 …See details»
Clene Provides Update on ALS Clinical Development Meeting With …
Dec 21, 2023 Clene met with the FDA to discuss CNM-Au8 ® for the treatment of ALS, presenting initial clinical and Neurofilament Light Chain (NfL) biomarker results from the …See details»
Clene Inc. - Press Releases
Sep 16, 2024 Clene met with the U.S. Food and Drug Administration (FDA) on November 1, 2024, in a Type C meeting to discuss the potential for an accelerated approval pathway in ALS …See details»
Team | Clene Inc.
He joins Clene alongside his current role as professor of neurology and Vice Chair of Clinical and Translational Research in the Department of Neurology at UT Southwestern Medical Center in …See details»
Clene Inc. (NASDAQ: CLNN) Announces Plan to Submit
Jul 18, 2024 Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS …See details»
Clene Reports Third Quarter 2024 Financial Results and Recent …
Nov 13, 2024 Clene met with the U.S. Food and Drug Administration (FDA) on November 1, 2024, in a Type C meeting to discuss the potential for an accelerated approval pathway in ALS …See details»
Clene Reports Third Quarter 2024 Financial Results and
Nov 13, 2024 Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical …See details»
Clene Inc. (CLNN) Stock Price, Quote & News - Stock Analysis
3 days ago Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) …See details»
Clene Inc. (CLNN) Stock Price, News, Quote & History - Yahoo …
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug …See details»
Patients | Clene Inc.
The World Health Organization predicts neurodegenerative diseases will become the second-most prevalent cause of death within the next 20 years 1.With this sense of urgency, we are …See details»
Clene Inc. (CLNN) Latest Stock News & Headlines - Yahoo Finance
IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership. This article was published by IBN, a multifaceted communications organization …See details»
Clene Inc. - Clene Reports Full Year 2020 Operating and Financial ...
Dec 31, 2020 Clene Reports Full Year 2020 Operating and Financial Highlights. March 29, 2021. PDF Version. Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain …See details»
Pipeline | Clene Inc.
CNM-Au8 ®. CNM-Au8 ® is a gold nanocrystal suspension currently in development as a disease-modifying treatment for people living with Amyotrophic Lateral Sclerosis (ALS), …See details»